Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
复制标题
血浆生长激素是晚期肝细胞癌患者中对阿托唑珠单抗和贝伐单抗反应的潜在生物标志物。
DOI：
10.18632/oncotarget.28322
复制
发表时间：
2022-12-06
期刊：
影响因子：
--
通讯作者：
Kaseb, Ahmed Omar
中科院分区：
文献类型：
--
作者：
Mohamed, Yehia I;Duda, Dan G;Awiwi, Muhammad O;Lee, Sunyoung S;Altameemi, Lina;Xiao, Lianchun;Morris, Jeffrey S;Wolff, Robert A;Elsayes, Khaled M;Hatia, Rikita I;Qayyum, Aliya;Chamseddine, Shadi M;Rashid, Asif;Yao, James C;Mahvash, Armeen;Hassan, Manal M;Amin, Hesham M;Kaseb, Ahmed Omar
简介：肝细胞癌（HCC）在发现晚期时有有限的全身治疗选择。因此，需要一种可获得的、微创的生物标志物来指导患者的治疗选择。本研究探讨了血浆生长激素（GH）水平的生物标志物价值，作为一种潜在的生物标志物，用于预测接受目前标准疗法atezolizumab + bevacizumab （Atezo/Bev）治疗的不可切除HCC患者的预后。材料和方法：研究纳入了计划接受Atezo/Bev治疗的不可切除的HCC患者。随访患者以确定无进展生存期（PFS）和总生存期（OS）。采用ELISA法测定血浆GH水平，并将HCC患者分为GH高组和GH低组（女性和男性GH正常临界值分别为≤3.7 μg/L和≤0.9 μg/L）。采用Kaplan-Meier法计算中位OS和PFS，采用Log rank检验比较高h组和低h组的生存结局。结果：本分析纳入37例患者，其中男性31例，女性6例，中位年龄67岁（37-80岁）。在分析时，生长激素低患者的一年生存率为70% (95% CI: 0.51, 0.96)，生长激素高患者的一年生存率为33% （95% CI: 0.16, 0.67）。低gh患者的OS明显优于高gh患者（中位OS: 18.9个月vs 9.3个月；p = 0.014）。与高gh组相比，低gh组患者的PFS无显著趋势（中位PFS: 6.6 vs 2.9个月；p = 0.053）。讨论和结论：血浆GH是预测晚期HCC患者Atezo/Bev治疗结果的生物标志物候选物。这一发现应该在晚期HCC患者的更大规模随机临床试验中得到进一步验证。
Introduction: Hepatocellular carcinoma (HCC) has limited systemic therapy options when discovered at an advanced stage. Thus, there is a need for accessible and minimally invasive biomarkers of response to guide the selection of patients for treatment. This study investigated the biomarker value of plasma growth hormone (GH) level as a potential biomarker to predict outcome in unresectable HCC patients treated with current standard therapy, atezolizumab plus bevacizumab (Atezo/Bev). Materials and Methods: Study included unresectable HCC patients scheduled to receive Atezo/Bev. Patients were followed to determine progression-free survival (PFS) and overall survival (OS). Plasma GH levels were measured by ELISA and used to stratify the HCC patients into GH-high and GH-low groups (the cutoff normal GH levels in women and men are ≤3.7 μg/L and ≤0.9 μg/L, respectively). Kaplan-Meier method was used to calculate median OS and PFS and Log rank test was used to compare survival outcomes between GH-high and -low groups. Results: Thirty-seven patients were included in this analysis, of whom 31 were males and 6 females, with a median age of 67 years (range: 37–80). At the time of the analysis, the one-year survival rate was 70% (95% CI: 0.51, 0.96) among GH low patients and 33% (95% CI: 0.16, 0.67) among GH high patients. OS was significantly superior in GH-low compared to GH-high patients (median OS: 18.9 vs. 9.3 months; p = 0.014). PFS showed a non-significant trend in favor of GH-low patients compared to the GH-high group (median PFS: 6.6 vs. 2.9 months; p = 0.053). Discussion and conclusions: Plasma GH is a biomarker candidate for predicting treatment outcomes in advanced HCC patients treated with Atezo/Bev. This finding should be further validated in larger randomized clinical trials in advanced HCC patients.